Although FLT3 is a well-characterized oncoprotein in AML, and its role as an important player in AML leukemogenesis established, our knowledge of the normal and pathologic FLT3 signaling network may still be inadequate for identification of the most effective therapeutic approach, as there are many aspects of the mutation we do not fully comprehend. This evidence concerns the gene FLT3 and acute myeloid leukemia.